文献速递眼底病与葡萄膜炎

残余视网膜液体对新生血管性年龄相关性黄斑变性治疗结局的影响

Impact of residual retinal fluid on treatment outcomes in neovascular age-related macular degeneration.
PubMed 文献 · Br J Ophthalmol · 2025-02-24

本文基于文献综述和国际视网膜专家组的临床经验,探讨残余视网膜液体对新生血管性年龄相关性黄斑变性(nAMD)个体化治疗决策与结局的影响,提出依据液体状态判断 Anti-VEGF 治疗时机的专家指导与算法,并讨论 OCT 识别液体的局限及「任何残余液体均反映持续 VEGF 活性」这一假设。

要点

  • OCT 上视网膜液体是 nAMD 疾病活动的主要标志和 Anti-VEGF 再治疗触发点。
  • 需区分不同解剖腔室及治疗不同阶段的残余液体,以指导个体化治疗。
  • 识别与解读 OCT 液体存在局限,「残余液体即持续 VEGF 活性」的假设受到讨论。

核心结论

  • 基于文献综述和国际视网膜专家组临床经验,本文按液体状态提供 nAMD 治疗专家指导,并提出依据残余液体状态决定 Anti-VEGF 给药时机的算法。

研究设计与样本

  • 文献综述结合国际视网膜专家组临床经验。

主要发现

  • 个体化治疗方案下 nAMD 治疗决策依据疾病活动调整,OCT 上视网膜液体是主要活动标志和再治疗触发点。
  • 残余视网膜液体对 nAMD 管理的影响近期受到关注,需考虑液体评估并区分不同解剖腔室及治疗不同阶段的液体。
  • 识别和解读 OCT 液体存在当前局限,且「任何残余视网膜液体反映持续 VEGF 活性」这一假设受到讨论。

临床怎么用

  • 本文提出依据残余液体状态决定何时给予 Anti-VEGF 治疗的算法,供个体化治疗中参考。

局限性

  • 识别和解读 OCT 上液体存在当前局限。
  • 「任何残余视网膜液体反映持续 VEGF 活性」的假设存在局限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Treatment decisions for neovascular age-related macular degeneration (nAMD) in the setting of individualised treatment regimens are adapted to disease activity. The main marker of disease activity and trigger for re-treatment with anti-vascular endothelial growth factor (anti-VEGF) agents is the presence of retinal fluid on optical coherence tomography (OCT). Recently, attention has focused on the impact of residual retinal fluid on nAMD management. Based on a literature review and the combined clinical experience of an international group of retinal specialists, this manuscript provides expert guidance on the treatment of nAMD according to fluid status and proposes an algorithm for determining when to administer anti-VEGF treatment according to residual fluid status. We explore the role of residual fluid in treatment decisions and outcomes in nAMD, taking into consideration fluid evaluation and, in particular, distinguishing between fluid in different anatomic compartments and at different stages during the treatment course. Current limitations to identifying and interpreting fluid on OCT, and the assumption that any residual retinal fluid reflects ongoing VEGF activity, are discussed.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Zur D, Guymer R, Korobelnik JF, et al. Impact of residual retinal fluid on treatment outcomes in neovascular age-related macular degeneration. Br J Ophthalmol. 2025. PMID: 39033013. doi:10.1136/bjo-2024-325640

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。